📜 What This Document Is ℹ️

This document is a Proxy Statement (DEF 14A). Think of it as the official instruction manual and corporate report card for an annual shareholder meeting. It's filed with the SEC and is mandatory for Ligand Pharmaceuticals Incorporated ("Ligand") to provide all of its stockholders with critical information they need before voting.

The statement covers everything that will be discussed and voted on, including who should be on the Board of Directors, how management is paid, and the company's overall health. 👉 This document does not represent the company's opinion but rather provides the necessary facts and proposals for the stockholders to make informed decisions.

🔬 Ligand Pharmaceuticals' Core Business 🧬

In simple terms, Ligand Pharmaceuticals is a biopharmaceutical royalty company. They don't typically develop drugs themselves; instead, they make their money by investing in and structuring financial rights—called royalty interests—from high-value medicines developed by other companies.

Ligand's primary strategy is to generate non-dilutive, long-duration cash flows by building a diverse portfolio of royalty streams. They achieve this through several ways:

• Royalty Purchases: Buying streams of revenue from successful drugs.
• Deal Structures: Investing in development-stage assets or acquiring companies with embedded royalty rights.
• Platform Technologies: Operating two infrastructure-light technologies, Captisol® and NITRICIL®, which generate royalties and contract revenue from partners.

👉 Their goal is to give investors exposure to drug innovation without the massive, binary risk (the risk of failing) and high capital costs that traditional drug development involves.

💰 2025 Operational & Financial Highlights 🚀

Ligand framed 2025 as a "defining year" due to exceptional financial performance and strategic execution. The company highlighted strong growth in its revenue streams, driven by portfolio success and a disciplined investment approach.

• Revenue Growth: Full-year royalty revenue grew 48% over the prior year.
  • Why it matters: This robust growth indicates that Ligand's investments in various drug assets are translating into strong, increasing cash flows from their partners.
• Earnings Performance: Full-year adjusted EPS increased 42%, surpassing the original 2025 guidance by more than 30%.
  • Why it matters: The significant beat on adjusted earnings suggests that the company's strategic focus and lean operating structure are highly effective in generating value for shareholders.
• Key Drivers: The growth was fueled by successful commercializations from partners, including Merck's Ohtuvayre and Capvaxive, and continued strength from Travere Therapeutics’ Filspari and Recordati’s Qarziba.
  • Why it matters: Ligand’s success is tied directly to the commercial success of its partners' drugs, demonstrating the royalty model's strength.
• Major Deal: In 2025, Ligand executed a strategic transaction that resulted in the merger of its Pelthos Therapeutics business with Channel Therapeutics, creating a new subsidiary, LNHC, Inc.
  • Why it matters: This was a successful "special situations transaction" that allowed Ligand to structure and monetize an asset, creating significant equity and royalty value.

💡 Future Strategy & Growth Initiatives 🌠

Looking forward, Ligand plans to accelerate its business development efforts in 2026. The company emphasizes increasing its capacity for high-potential investments and strengthening its portfolio management.

• Systematic Strategy: Ligand launched a systematic portfolio management strategy to drive value in its development-stage partnerships.
  • Why it matters: This indicates a move toward a more disciplined, predictable way of managing its investments, rather than relying solely on large, one-off transactions.
• Origination: The team is committed to identifying new opportunities through a combination of proprietary sourcing, deep industry relationships, and active engagement with biopharma partners.
  • Why it matters: This "disciplined origination process" allows them to evaluate opportunities early and structure transactions with precision, enhancing the quality of their investments.
• Technology Focus: The company operates on two platform technologies, Captisol® and NITRICIL®, which are designed to be scalable and infrastructure-light.
  • Why it matters: These platforms represent stable, core revenue streams that complement their royalty portfolio.

👥 Governance and Board Structure ⚖️

The board structure and governance policies are fundamental to maintaining transparency and good corporate leadership. Ligand has nominated eight directors, who will serve until the 2027 annual meeting.

• Board Size and Independence: The Board has a size of eight directors, with seven of them classified as independent.
  • Why it matters: High independence helps ensure that the Board can oversee management decisions without potential conflicts of interest.
• Leadership Structure: The company follows a structure where the CEO sets the strategy, and the Chairman of the Board provides guidance and presides over meetings.
  • Why it matters: This separation of roles is a standard governance practice designed to improve oversight and decision-making.
• Dedicated Committees: The Board utilizes specialized committees (like the Audit Committee, Nominating & Corporate Governance Committee, and Human Capital Management and Compensation Committee) to focus on specific high-risk areas.
  • Why it matters: These committees provide granular, expert oversight, ensuring that complex issues like accounting and executive pay are handled by specialists.

🧑‍⚖️ The Annual Meeting and Voting Mechanics 🗳️

The proxy statement outlines the mechanics of the upcoming annual meeting to ensure stockholders know exactly how and when to vote.

• Meeting Date and Time: The annual meeting is scheduled for Friday, June 5, 2026, starting at 8:30 am Pacific Time (11:30 am Eastern Time).
• Record Date: To be eligible to vote, stockholders must be of record by the close of business on Thursday, April 16, 2026.
• Attendance: The meeting will be held virtually; there is no physical location. Stockholders can attend and vote online via the provided link: https://meetnow.global/MQ42GX6.
• Quorum: A quorum is necessary to hold a valid meeting. This requires a majority of the shares (10,019,168 shares out of 20,038,334 outstanding) to be present or represented by proxy.
  • Why it matters: Ensuring a quorum means there are enough votes to make any business conducted during the meeting legally binding.

👑 Executive Compensation Practices 💸

The company details its policies for compensating its executives, which are required to be reviewed by shareholders via an advisory vote ("Say-on-Pay").

• Design Philosophy: The compensation program is designed to align executive interests with stockholders' long-term value creation. A substantial portion of compensation is performance-based or "at risk."
• Anti-Misconduct Policies: To protect shareholders, Ligand implements strict policies, including:
  • Double-Trigger Acceleration: Equity awards only accelerate (vest) if there is both a change in control and the executive is terminated.
  • Clawback Policy: They maintain a clawback policy that requires recovering incentive pay if the company has an accounting restatement.
• Compensation Details: The Committee reviews external market data and runs an Annual Peer Group Analysis to ensure the pay is competitive and reasonable.
• Non-Employee Director Pay: The annual retainer for a Director (Member) is $42,000 (increasing to $45,000 on April 10, 2026). The Annual Retainer for the Chair is $35,000. Directors also receive specific annual and initial grants of stock options and RSUs (Restricted Stock Units).

📈 Board Nominations and Expertise 🧠

Ligand nominated eight highly experienced individuals to the Board, bringing deep expertise in life sciences, finance, and global regulatory affairs.

• The Deep Experience: The board includes experts from diverse fields, such as the Medical Doctors (Sabba, Dr. Gray) and those with deep Pharma R&D backgrounds (Dr. LaMattina, Dr. Kozarich, Dr. Zimmermann).
• Mr. Todd C. Davis' Background: As CEO, Mr. Davis brings over thirty years of experience in both operations and investing in the biopharma industry, having worked with firms like Apax Partners and founded his own investment firm.
• Diversity of Expertise: The board brings expertise in areas from Harvard Business School (Mr. Davis) to deep scientific research (Dr. Gray, Dr. Kozarich) and international regulatory compliance (Dr. Zimmermann).
  • Why it matters: This broad mix of knowledge helps the Board manage risk and make well-rounded decisions across scientific, financial, and regulatory domains.

🌿 ESG and Corporate Citizenship 🌎

Ligand outlined its commitments to sustainable practices and corporate citizenship, showing that ESG (Environmental, Social, and Governance) factors are integral to its operations.

• Environmental Efforts: In 2025, the company invested $2.6 million in solar power at Kansas University Innovation Park. They also implemented green initiatives and enhanced recycling programs to reduce their overall carbon footprint.
  • Why it matters: This shows a proactive commitment to reducing environmental impact, which is increasingly important to investors and regulators.
• Workplace Culture: The company emphasizes creating a workplace culture built on respect, accountability, and collaboration, offering programs for charitable giving and paid time off for community service.
  • Why it matters: Attracting and retaining top talent is critical in the competitive biopharma space, and a positive culture is seen as a key driver of innovation.
• Compliance: The board emphasizes risk oversight regarding operational, financial, legal, and regulatory functions, supported by internal reporting mechanisms like a private incidence hotline.

📞 Where to Get More Information 🌐

For those who wish to follow up or participate in the annual meeting, this section contains all the logistical details and contacts provided in the filing.

• Virtual Meeting Access: The meeting link is https://meetnow.global/MQ42GX6.
• Online/Proxy Materials: The statements and annual reports are available electronically at www.envisionreports.com/LGND.
• Technical Support: For technical issues during the meeting, participants can call 1-888-724-2416.
• Corporate Secretary Contact: For general proxy material requests or legal inquiries, the Secretary is Andrew Reardon, located at Ligand Pharmaceuticals Incorporated, 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.

---

🧠 The Analogy

Think of Ligand Pharmaceuticals like a highly specialized, professional property portfolio manager for cutting-edge medicines. Instead of buying bricks and mortar, they buy small, rights-based "pieces of ownership" (royalty interests) in powerful buildings (the drugs). They then use their unique expertise to restructure and manage these properties, ensuring that the income streams flow reliably to their investors, regardless of who the original owner or primary tenant is.

🧩 Final Takeaway

Ligand is successfully executing its royalty strategy, evidenced by 48% royalty revenue growth in 2025. The company is strengthening its governance and expanding its disciplined investment portfolio to capitalize on the continuous innovation in biopharmaceuticals.